Genmab

	23/9 11:26 af SwingSun	when you make contracts like that you 10 diff lawfirms and make em look the whole thing through independely, its common sence
	23/9 11:18 af SwingSun	ffs
	23/9 11:18 af SwingSun	they used one person inhouse only??
	23/9 11:18 af SwingSun	he should be crucified and pay the fault expences lol
	23/9 11:17 af SwingSun	they only care about whats in writing
	23/9 11:17 af StockBull	It is and thats the reason Genmab looking for new attorney
	23/9 11:17 af SwingSun	they dont care about whats formerly agreed
	23/9 11:17 af SwingSun	those are tough business people.
	23/9 11:16 af Sukkeralf	Genmab said quite early that they were in deep talks with only one partner so that mean Janssen must have been out for some time
	23/9 11:16 af SwingSun	its a disaster
	23/9 11:16 af SwingSun	the patent dates
	23/9 11:16 af SwingSun	what puzzles me is how can a bunch of lawq people miss this fact,,,,,
	23/9 11:15 af SwingSun	naa sukker its the deal with abbvie i think. someone got a bit disappointed,,,,but ofc it could be some kind of leverage also.
	23/9 11:15 af Sukkeralf	I actualy think its fair that Genmab takes part in the Halozyme thing but the patent expire thing seems ridicously unfair
	23/9 11:11 af Bulder	My thought
	23/9 11:10 af Sukkeralf	Could it be that Janssen just want Genmab to pay their Halozymes bit and throw in the big thing about patent expire just to frigthen Genmab
	23/9 11:05 af nohope	De udbetalte den fordi der var fastlagte valutakurser som løftede salget over grænsen.
	23/9 10:59 af E L	in hindsight, let's be glad they diversified a bit with big partners with Abbvie
	23/9 10:55 af BioShare	Der var noget mere kærlighed i luften da JNJ valgte at udbetale milestone til GEN for "næsten" at have nået salgstallene ;-) Mit gæt er at det helt sikkert er aftalen med Abbvie, som har kølet tingene ned.
	23/9 10:54 af SwingSun	yes stock this will happen all over now.
	23/9 10:53 af SwingSun	i simpel fodfejl ligner det...aftalen har jo været kendt længe.
	23/9 10:53 af Stockwatch1	We anticipate that it will take months before this is resolved, putting lots of uncertainty on the stock in the meantime. We are downgrading our rating to SELL and putting our TP under review.
	23/9 10:52 af Stockwatch1	Bryan Garnier: Genmab just announced to have initiated binding arbitration against its partner J&J over two different issues: 1/Share of royalty owed to Halozyme on the SubQ formulation and 2/Duration of Darzalex’s royalties payment. While the impact of the first one seems negligible, we believe the second one could have a significant impact.
	23/9 10:52 af SwingSun	det virker lidt sådan

	23/9 10:52 af SwingSun	men solgte gen patentet til jansen i 2012?
	23/9 10:52 af Solsen	Ingen tvivl om at det gør ondt på JNJ at betale 20+5% på dara-sc til andre.
	23/9 10:51 af Solsen	Stregerne er ødelagte og vi må finde nogle nye punkter at stige fra. Frem imod november tror jeg vi ser stigende interesse igen. Det nytter jo ikke at indregne værst tænkelige scenarie.
	23/9 10:50 af SwingSun	hvis noge nved hvem tak. :-)
	23/9 10:50 af SwingSun	vil gerne vide hvilke advokater der har været med til kontrakten i 2012
	23/9 10:49 af Bulder	De skriver jo. at de ikke vil kommentere.
	23/9 10:48 af SwingSun	de har f. fået den største kage næsten risikofrit.
	23/9 10:48 af SwingSun	det er tyndt af jansen,,,,
	23/9 10:47 af PederT	Mon ikke at han er bundet på hænder og fødder mht. hvad han må sige :)
	23/9 10:45 af Bulder	Vi kan håbe det ender med at Janssen betaler royalties indtil 2035 og at Genmab så accepterer at betale 2½% af Halo's royalty. Ville være en blød udgang.
	23/9 10:39 af E L	lol, i am not a lawyer
	23/9 10:37 af Mcjean	Are you moving to CPH?;-)
	23/9 10:33 af E L	(link) (link) :-D
	23/9 10:32 af Zipo	While Genmab intends to vigorously protect its rights under the agreement, the outcome of any arbitration proceeding, as well as its duration, is inherently uncertain.
	23/9 10:28 af PederT	Det står også i deres press release, at Genmab har påbegyndt sagen.
	23/9 10:28 af Zipo	(link) g-arbitration-two-matters-under-license
	23/9 10:26 af BioShare	Formentlig Genmab - JNJ er jo begyndt at reducere royalty-betalingen med HALO-andelen.
	23/9 10:26 af GeorgeBest	Genmab
	23/9 10:25 af w	Hvem af partnerne har indgivet sagen?
	23/9 10:21 af Sukkeralf	Patent bollocks - i just hate it :-( You have no chance just cold water right in the face !!
	23/9 10:17 af E L	by the way, Symphony Health data anyone...?
	23/9 10:15 af E L	I now really wonder why Genmab thought that non-compete clause with Dara was acceptable...
	23/9 10:13 af Zipo	Test
	23/9 10:11 af GeorgeBest	But wouldn’t that be an overlap with Epcoritamab?
	23/9 10:11 af GeorgeBest	Now we know why Jan want to develope Hexa-cd38 in B-cell lymphoma...
	23/9 10:09 af nohope	GEN ophører jo nærmest med at eksistere i 2030